The CD36-expressing tumor cell population represents a metastatic-prone subgroup of tumor cells, so SARIFA positivity combined with the assessment of tumor budding gives a new perspective to evaluate the potential of metastasis development [17,18]. This evidence concerns the gene CD36 and neoplasm.